How This Works
Vesugen (KED) is a tripeptide derived from amino acids associated with vascular wall proteins[1]. Research indicates it may support vascular endothelial cell proliferation by modulating the expression of Ki-67, a protein closely associated with cell division[2]. The peptide is hypothesized to interact with promoter regions of the Ki-67 gene, potentially influencing epigenetic regulation[3]. Additional studies suggest Vesugen may normalize endothelin-1 expression and increase sirtuin-1 (SIRT-1) expression in vascular endothelial cells[4].
References
Bull Exp Biol Med (2016)
— Short Peptides Regulate Gene Expression (Khavinson et al.)
Adv Gerontol (2014)
— Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging
Molecules (2021)
— Peptide Regulation of Gene Expression: A Systematic Review (MDPI)
Adv Gerontol (2016)
— Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis
Bull Exp Biol Med (2021)
— Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease
Bull Exp Biol Med (2017)
— Tripeptides Restore the Number of Neuronal Spines under Conditions of In Vitro Modeled Alzheimer’s Disease
Int J Mol Sci (2022)
— Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
Pharmaceuticals (2021)
— Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease
DailyMed
— Bacteriostatic Water measurement, solution (FDA labeling)
PMC (2024)
— Practical advice in the development of a lyophilized protein drug product
MedlinePlus
— (SQ) measurements: technique and site guidance
NCBI Bookshelf
— Best practices for measurement (WHO guidelines)
CDC
— Vaccine preparation: handling reference
Biogerontology (2010)
— Peptide bioregulation of aging: Results and prospects (Anisimov & Khavinson)
Stem Cell Rev Rep (2020)
— Peptide Regulation of Cell Differentiation
